Companies Horizon Therapeutics Public Ltd
Horizon Therapeutics Public (HZNP): executive pay, fiscal 2022
Free brief. Every figure links to the company’s own filing.
Horizon Therapeutics Public Ltd no longer files a proxy statement; its last pay data is FY2022.
CEO vs. named peers54th pct.Of 13 peer CEOs
CEO pay, last three years
- $21,632,803FY2020
- $21,353,458FY2021
- $20,103,869FY2022
CEO total pay was $20,103,869 in fiscal 2022, down from $21,353,458 in fiscal 2021.
FY2022: salary $1,292,727 · bonus $1,681,324 · stock awards $16,601,305 · option awards $0
Frequently asked questions
Who was the highest-paid executive at Horizon Therapeutics Public Ltd in fiscal 2022?
As disclosed, Timothy Walbert (Chairman, President and Chief Executive Officer) was the highest-paid executive at Horizon Therapeutics Public Ltd in fiscal 2022, with total compensation of $20,103,869.
How does Horizon Therapeutics Public Ltd's chief executive pay compare to its disclosed peer group?
As disclosed, Timothy Walbert's total compensation ranked at the 54th percentile of Horizon Therapeutics Public Ltd's disclosed peer group.
What is Horizon Therapeutics Public Ltd's CEO-to-median employee pay ratio?
As disclosed, Horizon Therapeutics Public Ltd's CEO-to-median employee pay ratio was 76:1.
How much does Horizon Therapeutics Public Ltd spend in total on board compensation for fiscal 2022?
As disclosed, Horizon Therapeutics Public Ltd reported total board compensation of $4,100,521 for fiscal 2022.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Timothy Walbert | $1,292,727 | $1,681,324 | $16,601,305 | $0 | $0 | $0 | $528,513 | $20,103,869 |
| Chairman, President and Chief Executive Officer | ||||||||
| Sean Clayton | 547,685 | 6,382,699 | 3,839,414 | 0 | 0 | 0 | 102,409 | 10,872,207 |
| Executive Vice President, General Counsel | ||||||||
| Elizabeth Thompson | 594,167 | 2,915,998 | 4,819,700 | 0 | 0 | 0 | 151,155 | 8,481,020 |
| Executive Vice President, Research and Development | ||||||||
| Aaron Cox | 640,667 | 448,554 | 5,817,498 | 0 | 0 | 0 | 267,824 | 7,174,543 |
| Executive Vice President, Chief Financial Officer | ||||||||
| Andy Pasternak | 719,506 | 503,752 | 5,355,203 | 0 | 0 | 0 | 174,333 | 6,752,794 |
| Executive Vice President, Chief Strategy Officer | ||||||||
| Paul Hoelscher | 249,792 | 172,142 | 928,871 | 0 | 0 | 0 | 471,776 | 1,822,581 |
| Former Executive Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Timothy Walbert | $20,103,869 | $21,353,458 | $21,632,803 | ↓ −1,249,589 |
| Sean Clayton | 10,872,207 | — | — | — |
| Elizabeth Thompson | 8,481,020 | — | — | — |
| Aaron Cox | 7,174,543 | — | — | — |
| Andy Pasternak | 6,752,794 | 6,947,326 | 5,826,126 | ↓ −194,532 |
| Paul Hoelscher | 1,822,581 | 7,343,656 | 5,915,146 | ↓ −5,521,075 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Horizon provides a competitive total compensation package through a combination of base salary, short-term performance-based cash incentives, and long-term performance-based equity incentives. The program is designed to align the interests of executive officers, employees, patients, and shareholders by motivating the achievement of performance objectives that benefit the company and increase shareholder value, while attracting and retaining talented executives.
| CEO STI target (% of salary) | 130% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2022
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Timothy Walbert | RSU | 2022-01-04 | — | — | 73,796 | — | $7,198,800 |
| Elizabeth Thompson | RSU | 2022-01-04 | — | — | 21,424 | — | 2,089,911 |
| Elizabeth Thompson | RSU | 2022-01-04 | — | — | 21,425 | — | 2,729,789 |
| Aaron Cox | RSU | 2022-01-04 | — | — | 23,805 | — | 2,522,616 |
| Andy Pasternak | RSU | 2022-01-04 | — | — | 23,805 | — | 2,322,178 |
| Sean Clayton | RSU | 2022-03-01 | — | — | 42,387 | — | 3,839,414 |
| Andy Pasternak | RSU | 2022-01-04 | — | — | 23,805 | — | 3,033,025 |
| Timothy Walbert | RSU | 2022-01-04 | — | — | 73,797 | — | 9,402,505 |
| Paul Hoelscher | RSU | 2022-01-04 | — | — | 9,522 | — | 928,871 |
| Aaron Cox | RSU | 2022-01-04 | — | — | 23,805 | — | 3,294,882 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Timothy Walbert | $16,601,305 | $0 | $0 | 0.0% |
| Elizabeth Thompson | 4,819,700 | 0 | 0 | 0.0% |
| Aaron Cox | 5,817,498 | 0 | 0 | 0.0% |
| Andy Pasternak | 5,355,203 | 0 | 0 | 0.0% |
| Sean Clayton | 3,839,414 | 0 | 0 | 0.0% |
| Paul Hoelscher | 928,871 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Aaron Cox | RSU | 4,654 | — | $529,625 |
| Elizabeth Thompson | RSU | 4,657 | — | 529,967 |
| Andy Pasternak | RSU | 5,816 | — | 661,861 |
| Aaron Cox | RSU | 9,314 | — | 1,059,933 |
| Paul Hoelscher | RSU | 9,522 | — | 1,083,604 |
| Andy Pasternak | RSU | 11,643 | — | 1,324,973 |
| Elizabeth Thompson | RSU | 14,283 | — | 1,625,405 |
| Aaron Cox | RSU | 15,870 | — | 1,806,006 |
| Andy Pasternak | RSU | 15,870 | — | 1,806,006 |
| Paul Hoelscher | RSU | 17,464 | — | 1,987,403 |
| Elizabeth Thompson | RSU | 18,940 | — | 2,155,372 |
| Elizabeth Thompson | PSU | 21,425 | — | 2,438,165 |
| Paul Hoelscher | RSU | 23,286 | — | 2,649,947 |
| Aaron Cox | PSU | 23,805 | — | 2,709,009 |
| Andy Pasternak | PSU | 23,805 | — | 2,709,009 |
| Paul Hoelscher | PSU | 26,196 | — | 2,981,105 |
| Andy Pasternak | PSU | 26,196 | — | 2,981,105 |
| Aaron Cox | RSU | 29,838 | — | 2,865,939 |
| Andy Pasternak | RSU | 33,329 | — | 3,792,840 |
| Sean Clayton | RSU | 42,387 | — | 4,823,641 |
| Paul Hoelscher | RSU | 42,993 | — | 4,892,603 |
| Aaron Cox | PSU | 44,762 | — | 5,093,916 |
| Andy Pasternak | PSU | 50,001 | — | 5,690,114 |
| Timothy Walbert | RSU | 52,392 | — | 5,962,210 |
| Timothy Walbert | RSU | 58,055 | — | 6,606,659 |
| Timothy Walbert | RSU | 69,857 | — | 7,949,727 |
| Timothy Walbert | RSU | 73,796 | — | 8,397,985 |
| Timothy Walbert | PSU | 73,797 | — | 8,398,099 |
| Timothy Walbert | PSU | 78,589 | — | 8,943,428 |
| Paul Hoelscher | RSU | 102,787 | — | 11,697,161 |
| Timothy Walbert | RSU | 171,968 | — | 19,569,958 |
| Timothy Walbert | RSU | 2,392,565 | — | 272,273,897 |
| Timothy Walbert | PSU | 48,486,539 | — | 5,517,768,138 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael GreyIndependent · Lead Independent Director · Audit (Chair) · Nominating and Corporate Governance | $151,250 | $399,987 | $0 | — | $0 | $551,237 |
| William F. DanielIndependent · Audit · Compensation | 112,500 | 399,987 | 0 | — | 10,000 | 522,487 |
| Susan Mahony, Ph.DIndependent · Compensation | 114,375 | 399,987 | 0 | — | 0 | 514,362 |
| James Shannon, M.DIndependent · Nominating and Corporate Governance | 110,625 | 399,987 | 0 | — | 0 | 510,612 |
| H. Thomas WatkinsIndependent · Audit · Nominating and Corporate Governance | 106,250 | 399,987 | 0 | — | 0 | 506,237 |
| Jeff Himawan, Ph.DIndependent · Compensation | 104,375 | 399,987 | 0 | — | 0 | 504,362 |
| Pascale WitzIndependent · Audit · Nominating and Corporate Governance | 96,250 | 399,987 | 0 | — | 0 | 496,237 |
| Gino SantiniIndependent · Compensation | 95,000 | 399,987 | 0 | — | 0 | 494,987 |
| Timothy P. WalbertEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $75,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 25,000 / 20,000 |
| Stock ownership guideline | $5 |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $890,625 |
| Equity awards (grant-date value) | $3,199,896 |
| All other compensation | $10,000 |
| Total cost of the board | $4,100,521 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Horizon Therapeutics Public as a peer
Companies that benchmark against HZNP
1 company names HZNP as a compensation peer
The list of companies that name HZNP as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2022
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
BIIB Biogen, Inc.OLMA Alexion Pharmaceuticals, Inc.ALNY Alnylam Pharmaceuticals, Inc.BMRN BioMarin Pharmaceutical Inc.EXEL Exelixis, Inc.INCY Incyte CorporationIONS Ionis Pharmaceuticals, Inc.NBIX Neurocrine Biosciences, Inc.REGN Regeneron Pharmaceuticals, Inc.SGEN Seagen, Inc.UTHR United Therapeutics CorporationVRTX Vertex Pharmaceuticals Inc.JAZZ Jazz Pharmaceuticals plc
Peer reciprocity
The companies Horizon Therapeutics Public Ltd names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Seagen, Inc. | 2022 | David Epstein | $190,385 | $14,815,386 | $42,381,246 | $0 | $57,460,546 |
| 2 | Exelixis, Inc. | 2025 | Michael Morrissey | 1,306,040 | 30,539,552 | 0 | 1,382,591 | 33,239,183 |
| 3 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 4 | Biogen, Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 5 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 6 | Vertex Pharmaceuticals Inc. | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 7 | Horizon Therapeutics Public Ltd | 2022 | Timothy Walbert | 1,292,727 | 16,601,305 | 0 | 0 | 20,103,869 |
| 8 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 9 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 10 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 11 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 12 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 13 | Regeneron Pharmaceuticals, Inc. | 2025 | Leonard Schleifer | 1,979,922 | — | — | 3,682,655 | 7,280,549 |
| 14 | Alexion Pharmaceuticals, Inc. | 2025 | Sean Bohen | 699,920 | 0 | 2,002,000 | 461,900 | 3,178,990 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Horizon Therapeutics Public Ltd | 100% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon |
| Alexion Pharmaceuticals, Inc. | 110% | Options 100 | not disclosed | Aon |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| Biogen, Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Neurocrine Biosciences, Inc. | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Regeneron Pharmaceuticals, Inc. | 155% | Options 60 · RSU 40 | not disclosed | Pay Governance LLC |
| Seagen, Inc. | 130% | RSU 60 · PSU 40 | Yes — Relative TSR | Aon |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
| Vertex Pharmaceuticals Inc. | not disclosed | PSU 55 · RSU 45 | No | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 76 : 1 |
|---|---|
| CEO total compensation | $20,103,869 |
| Median employee compensation | $264,751 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jeff Himawan | Director | 2023-09-26 | D | 32,161 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Jeff Himawan | Director | 2023-09-26 | A | 32,161 | 14 | 446,073 | Common | Form 4 ↗ |
| Michael Grey | Director | 2023-09-28 | A | 20,000 | 16 | 319,200 | Common | Form 4 ↗ |
| Michael Grey | Director | 2023-09-28 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-09-29 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-09-29 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-09-29 | A | 21,323 | 14 | 295,750 | Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-09-29 | A | 20,000 | 16 | 319,200 | Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-09-29 | A | 40,000 | 12 | 491,600 | Common | Form 4 ↗ |
| James Samuel Shannon | Director | 2023-09-29 | D | 11,850 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Samuel Shannon | Director | 2023-09-29 | A | 11,850 | 12 | 144,452 | Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-09-29 | D | 21,323 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gino Santini | Director | 2023-10-02 | D | 23,092 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gino Santini | Director | 2023-10-02 | A | 23,092 | 15 | 351,691 | Common | Form 4 ↗ |
| Pascale Witz | Director | 2023-10-06 | D | 4,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Pascale Witz | Director | 2023-10-06 | D | 32,161 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Pascale Witz | Director | 2023-10-06 | D | 52,232 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Pascale Witz | Director | 2023-10-06 | D | 20,279 | 117 | 2,362,504 | Common | Form 4 ↗ |
| Pascale Witz | Director | 2023-10-06 | D | 25,672 | 117 | 2,990,788 | Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 5,749 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 11,499 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 23,806 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 14,282 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 4,761 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 34,928 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 5,816 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 15,281 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 22,997 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 15,870 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 11,643 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 5,749 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 5,749 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 11,499 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 23,806 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 14,282 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 4,761 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 27,942 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 4,654 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 12,226 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 22,997 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 15,870 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 9,314 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Cox | EVP, Chief Financial Officer | 2023-10-06 | D | 556 | 117 | 64,774 | Common | Form 4 ↗ |
| Gino Santini | Director | 2023-10-06 | D | 4,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gino Santini | Director | 2023-10-06 | D | 32,161 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gino Santini | Director | 2023-10-06 | D | 31,153 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gino Santini | Director | 2023-10-06 | D | 8,548 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gino Santini | Director | 2023-10-06 | D | 18,655 | 117 | 2,173,308 | Common | Form 4 ↗ |
| Gino Santini | Director | 2023-10-06 | D | 100,959 | 117 | 11,761,724 | Common | Form 4 ↗ |
| Sean Clayton | EVP, General Counsel | 2023-10-06 | D | 11,499 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sean Clayton | EVP, General Counsel | 2023-10-06 | D | 5,749 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sean Clayton | EVP, General Counsel | 2023-10-06 | D | 5,749 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sean Clayton | EVP, General Counsel | 2023-10-06 | D | 22,997 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sean Clayton | EVP, General Counsel | 2023-10-06 | D | 28,258 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sean Clayton | EVP, General Counsel | 2023-10-06 | D | 745 | 117 | 86,793 | Common | Form 4 ↗ |
| Sean Clayton | EVP, General Counsel | 2023-10-06 | D | 7,655 | 117 | 891,808 | Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 5,174 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 5,174 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 4,285 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 12,854 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 21,426 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 20,697 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 14,283 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 4,657 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 17,823 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 17,823 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 35,645 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 44,278 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 14,759 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 104,786 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 17,448 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 45,843 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 71,290 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 49,198 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 34,929 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 1,650,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 742,565 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William F. Daniel | Director | 2023-10-06 | D | 32,161 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William F. Daniel | Director | 2023-10-06 | D | 31,153 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 49,935 | 117 | 5,817,428 | Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 100,300 | 117 | 11,684,950 | Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 107,739 | 117 | 12,551,594 | Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 616,772 | 117 | 71,853,938 | Common | Form 4 ↗ |
| William F. Daniel | Director | 2023-10-06 | D | 23,092 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William F. Daniel | Director | 2023-10-06 | D | 8,548 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William F. Daniel | Director | 2023-10-06 | D | 13,286 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William F. Daniel | Director | 2023-10-06 | D | 31,915 | 117 | 3,718,098 | Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-10-06 | D | 4,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-10-06 | D | 10,838 | — | — | Derivative, Class A Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-10-06 | D | 31,153 | — | — | Derivative, Class A Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-10-06 | D | 23,092 | — | — | Derivative, Class A Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-10-06 | D | 8,548 | — | — | Derivative, Class A Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-10-06 | D | 10,000 | 117 | 1,165,000 | Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-10-06 | D | 55,953 | 117 | 6,518,525 | Common | Form 4 ↗ |
| H. Thomas Watkins | Director | 2023-10-06 | D | 110,447 | 117 | 12,867,076 | Common | Form 4 ↗ |
| Michael Grey | Director | 2023-10-06 | D | 4,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Grey | Director | 2023-10-06 | D | 32,161 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Grey | Director | 2023-10-06 | D | 31,153 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Grey | Director | 2023-10-06 | D | 23,092 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Grey | Director | 2023-10-06 | D | 8,548 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Grey | Director | 2023-10-06 | D | 10,000 | 117 | 1,165,000 | Common | Form 4 ↗ |
| Michael Grey | Director | 2023-10-06 | D | 48,031 | 117 | 5,595,612 | Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 56,338 | 117 | 6,563,377 | Common | Form 4 ↗ |
| Michael Grey | Director | 2023-10-06 | D | 39,361 | 117 | 4,585,557 | Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 5,174 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 5,174 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 10,349 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 21,426 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 12,854 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 4,285 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 31,436 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 5,236 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 13,753 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 20,697 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 14,283 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 10,479 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael A. DesJardin | EVP, Technical Operations | 2023-10-06 | D | 126,838 | 117 | 14,776,627 | Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 9,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 4,599 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 4,599 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 19,044 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 11,426 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 3,809 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 27,942 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 4,654 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 12,226 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 18,397 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 12,696 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 9,314 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 164,469 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 45,352 | 117 | 5,283,508 | Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 80,944 | 117 | 9,429,976 | Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 105,808 | 117 | 12,326,632 | Common | Form 4 ↗ |
| Jeffrey W. Sherman | EVP and Chief Medical Officer | 2023-10-06 | D | 2,655 | 117 | 309,308 | Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 10,349 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Walbert | Director | 2023-10-06 | D | 73,798 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Thompson | EVP, Research & Development | 2023-10-06 | D | 5,174 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Thompson | EVP, Research & Development | 2023-10-06 | D | 5,174 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Thompson | EVP, Research & Development | 2023-10-06 | D | 10,349 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Thompson | EVP, Research & Development | 2023-10-06 | D | 21,426 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Thompson | EVP, Research & Development | 2023-10-06 | D | 12,854 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Thompson | EVP, Research & Development | 2023-10-06 | D | 4,285 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Thompson | EVP, Research & Development | 2023-10-06 | D | 20,697 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Thompson | EVP, Research & Development | 2023-10-06 | D | 14,283 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Thompson | EVP, Research & Development | 2023-10-06 | D | 4,657 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Thompson | EVP, Research & Development | 2023-10-06 | D | 14,575 | 117 | 1,697,988 | Common | Form 4 ↗ |
| Andy Pasternak | EVP, Chief Strategy Officer | 2023-10-06 | D | 5,749 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick McIlvenny | Chief Accounting Officer | 2023-10-06 | D | 11,498 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick McIlvenny | Chief Accounting Officer | 2023-10-06 | D | 3,809 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick McIlvenny | Chief Accounting Officer | 2023-10-06 | D | 2,198 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick McIlvenny | Chief Accounting Officer | 2023-10-06 | D | 6,874 | 117 | 800,821 | Common | Form 4 ↗ |
| James Samuel Shannon | Director | 2023-10-06 | D | 4,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Samuel Shannon | Director | 2023-10-06 | D | 32,161 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Samuel Shannon | Director | 2023-10-06 | D | 8,150 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Samuel Shannon | Director | 2023-10-06 | D | 23,638 | 117 | 2,753,827 | Common | Form 4 ↗ |
| James Samuel Shannon | Director | 2023-10-06 | D | 33,156 | 117 | 3,862,674 | Common | Form 4 ↗ |
| Jeff Himawan | Director | 2023-10-06 | D | 4,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeff Himawan | Director | 2023-10-06 | D | 31,153 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeff Himawan | Director | 2023-10-06 | D | 23,092 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeff Himawan | Director | 2023-10-06 | D | 7,873 | 117 | 917,205 | Common | Form 4 ↗ |
| Jeff Himawan | Director | 2023-10-06 | D | 36,609 | 117 | 4,264,949 | Common | Form 4 ↗ |
| Jeff Himawan | Director | 2023-10-06 | D | 44,546 | 117 | 5,189,609 | Common | Form 4 ↗ |
| William F. Daniel | Director | 2023-10-06 | D | 4,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William F. Daniel | Director | 2023-10-06 | D | 47,670 | 117 | 5,553,555 | Common | Form 4 ↗ |
| Susan Mahony | Director | 2023-10-06 | D | 4,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susan Mahony | Director | 2023-10-06 | D | 9,306 | 117 | 1,084,149 | Common | Form 4 ↗ |
| Susan Mahony | Director | 2023-10-06 | D | 9,345 | 117 | 1,088,693 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (211 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Timothy Walbert. DEF 14A, filed 2023-06-30. Section “Summary Compensation Table”. As printed: 20,103,869. View filing ↗
- Section 01, Sean Clayton. DEF 14A, filed 2023-06-30. Section “Summary Compensation Table”. As printed: 10,872,207. View filing ↗
- Section 01, Elizabeth Thompson. DEF 14A, filed 2023-06-30. Section “Summary Compensation Table”. As printed: 8,481,020. View filing ↗
- Section 01, Aaron Cox. DEF 14A, filed 2023-06-30. Section “Summary Compensation Table”. As printed: 7,174,543. View filing ↗
- Section 01, Andy Pasternak. DEF 14A, filed 2023-06-30. Section “Summary Compensation Table”. As printed: 6,752,794. View filing ↗
- Section 01, Paul Hoelscher. DEF 14A, filed 2023-06-30. Section “Summary Compensation Table”. As printed: 1,822,581. View filing ↗
- Section 03, Timothy Walbert RSU. DEF 14A, filed 2023-06-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Elizabeth Thompson RSU. DEF 14A, filed 2023-06-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Elizabeth Thompson RSU. DEF 14A, filed 2023-06-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Aaron Cox RSU. DEF 14A, filed 2023-06-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andy Pasternak RSU. DEF 14A, filed 2023-06-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Sean Clayton RSU. DEF 14A, filed 2023-06-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andy Pasternak RSU. DEF 14A, filed 2023-06-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Timothy Walbert RSU. DEF 14A, filed 2023-06-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Paul Hoelscher RSU. DEF 14A, filed 2023-06-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Aaron Cox RSU. DEF 14A, filed 2023-06-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2023-06-30. Section “CEO Pay Ratio”. As printed: 76 : 1. View filing ↗
- Section 08, Michael Grey. DEF 14A, filed 2023-06-30. Section “Director Compensation”. As printed: 551,237. View filing ↗
- Section 08, William F. Daniel. DEF 14A, filed 2023-06-30. Section “Director Compensation”. As printed: 522,487. View filing ↗
- Section 08, Susan Mahony, Ph.D. DEF 14A, filed 2023-06-30. Section “Director Compensation”. As printed: 514,362. View filing ↗
- Section 08, James Shannon, M.D. DEF 14A, filed 2023-06-30. Section “Director Compensation”. As printed: 510,612. View filing ↗
- Section 08, H. Thomas Watkins. DEF 14A, filed 2023-06-30. Section “Director Compensation”. As printed: 506,237. View filing ↗
- Section 08, Jeff Himawan, Ph.D. DEF 14A, filed 2023-06-30. Section “Director Compensation”. As printed: 504,362. View filing ↗
- Section 08, Pascale Witz. DEF 14A, filed 2023-06-30. Section “Director Compensation”. As printed: 496,237. View filing ↗
- Section 08, Gino Santini. DEF 14A, filed 2023-06-30. Section “Director Compensation”. As printed: 494,987. View filing ↗
- Section 08, Timothy P. Walbert. DEF 14A, filed 2023-06-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Jeff Himawan 2023-09-26. Form 4, filed 2023-09-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Himawan 2023-09-26. Form 4, filed 2023-09-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Grey 2023-09-28. Form 4, filed 2023-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Grey 2023-09-28. Form 4, filed 2023-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-09-29. Form 4, filed 2023-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-09-29. Form 4, filed 2023-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-09-29. Form 4, filed 2023-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-09-29. Form 4, filed 2023-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-09-29. Form 4, filed 2023-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Samuel Shannon 2023-09-29. Form 4, filed 2023-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Samuel Shannon 2023-09-29. Form 4, filed 2023-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-09-29. Form 4, filed 2023-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gino Santini 2023-10-02. Form 4, filed 2023-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gino Santini 2023-10-02. Form 4, filed 2023-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pascale Witz 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pascale Witz 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pascale Witz 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pascale Witz 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pascale Witz 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Cox 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gino Santini 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gino Santini 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gino Santini 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gino Santini 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gino Santini 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gino Santini 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Clayton 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Clayton 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Clayton 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Clayton 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Clayton 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Clayton 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Clayton 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William F. Daniel 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William F. Daniel 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William F. Daniel 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William F. Daniel 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William F. Daniel 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William F. Daniel 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, H. Thomas Watkins 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Grey 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Grey 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Grey 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Grey 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Grey 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Grey 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Grey 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Grey 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. DesJardin 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Sherman 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Walbert 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Thompson 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Thompson 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Thompson 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Thompson 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Thompson 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Thompson 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Thompson 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Thompson 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Thompson 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Thompson 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andy Pasternak 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick McIlvenny 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick McIlvenny 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick McIlvenny 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick McIlvenny 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Samuel Shannon 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Samuel Shannon 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Samuel Shannon 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Samuel Shannon 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Samuel Shannon 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Himawan 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Himawan 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Himawan 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Himawan 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Himawan 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Himawan 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William F. Daniel 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William F. Daniel 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan Mahony 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan Mahony 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan Mahony 2023-10-06. Form 4, filed 2023-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 890,625 + equity 3,199,896 + all other 10,000 = 4,100,521, summed across the director compensation table rows.
- Seagen, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-18. CEO total compensation as printed in Seagen, Inc.'s own proxy. As printed: 57,460,546. View filing ↗
- Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
- Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
- Biogen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen, Inc.'s own proxy. As printed: 23,646,004. View filing ↗
- BioMarin Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. View filing ↗
- Vertex Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Vertex Pharmaceuticals Inc.'s own proxy. As printed: 21,144,261. View filing ↗
- Horizon Therapeutics Public Ltd (subject), Section 10b CEO total. DEF 14A, filed 2023-06-30. CEO total compensation as printed in Horizon Therapeutics Public Ltd's own proxy. As printed: 20,103,869. View filing ↗
- Jazz Pharmaceuticals plc, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. View filing ↗
- United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
- Alnylam Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. View filing ↗
- Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
- Ionis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. View filing ↗
- Regeneron Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. View filing ↗
- Alexion Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alexion Pharmaceuticals, Inc.'s own proxy. As printed: 3,178,990. View filing ↗
- Section 10a, Seagen, Inc. reciprocity. DEF 14A. Seagen, Inc. names Horizon Therapeutics Public Ltd in its own disclosed peer group (read from its most recent proxy). View filing ↗